TABLE 1

Clinical and Scintigraphic Findings

Patient no.	Age (y)	Sex	Diagnosis	Tumor location	Extratumoral tracer uptake			Local side effect
Patient no.	Age (y)	Sex	Diagnosis	Tumor location				Local side effect			Visual uptake score	Uptake ratio
1	29	M	Ewing’s sarcoma	L iliac bone	No	1.00	−
2	17	M	Osteosarcoma	L distal femur	No	1.00	−
3	65	F	MFH	R distal femur	Moderate	1.84	+
4	51	M	Metastasis from lung cancer	L thigh	High	4.48	+
5	67	F	Leiomyosarcoma	R forearm	No	1.00	−
					No	1.00	−
6	62	F	MFH	R thigh	Mild	1.33	−
7	14	F	Osteosarcoma	L pelvis	No	1.00	−
					No	1.00	−
8	35	F	Osteosarcoma	R humerus	No	1.00	−
					No	1.00	−
					Mild	1.13	−
					No	1.00	−
9	36	M	Liposarcoma	L thigh	Mild	2.13	−
10	66	F	Osteosarcoma	R pelvis	High	2.91	+
11	9	M	Osteosarcoma	L femur	Moderate	2.36	−
					High	4.50	+
					No	1.00	−
12	8	M	Osteosarcoma	R femur	High	9.70	+
13	69	M	Osteosarcoma	R ilium	No	1.00	−
14	14	F	Rhabdomyosarcoma	R forearm	No	1.00	−
15	11	M	Ewing’s sarcoma	L femur	Mild	2.31	−
16	52	M	MFH	L femur	High	7.37	+
					Moderate	3.40	−
					No	1.00	−
17	15	M	Eosinophilic granuloma	L acetabulum	Mild	1.41	−
18	27	M	Rhabdomyosarcoma	L first metatarsus	High	5.81	+
19	50	F	Clear cell sarcoma	R foot	Moderate	3.31	+
					Moderate	4.14	+
20	27	F	Ewing’s sarcoma	R tibia	High	7.37	+
					Moderate	3.43	−*
					Moderate	2.40	−*
					High	4.34	−*
21	18	M	Osteosarcoma	R humerus	Moderate	3.64	+
22	38	M	Osteosarcoma	L distal femur	Moderate	2.73	−*
					Moderate	3.00	−*
23	49	M	Leiomyosarcoma	Sacrum	High	5.00	−*
					No	1.00	−
					No	1.00	−
24	24	F	Myxoid liposarcoma	L ankle	Moderate	2.48	−*
					Moderate	2.26	−*
					No	1.00	−

↵* Doxorubicin and caffeine administration were changed to intravenous route.
MFH = malignant fibrous histiocytoma.